Described are mevalonate diphosphate decarboxylase variants having improved activity in converting 3-phosphonoxyisovalerate into isobutene. Such variants can be employed in processes for biologically producing isobutene from 3-hydroxyisovalerate or from 3-hydroxy-3-methylbutyrate into isobutene, for biologically producing isoprenol from mevalonate or from mevalonate-3-phosphate or for biologically producing 1,3-butadiene from 3-hydroxypent-4-enoate or from 3-phosphonoxypent-4-enoate. Also described is an enzyme which is characterized in that it is capable of converting 3-phosphonoxyisovalerate into isobutene with a kcat of more than 0.1 s.sup.−1.

A process comprising (i) providing a gaseous stream including greater than 1% by volume carbon dioxide; (ii) providing water; (iii) converting the carbon dioxide and the water to an organic intermediate and oxygen gas in the presence of light; (iv) separating the oxygen gas from the organic intermediate; and (v) converting the organic intermediate to ethylene and carbon dioxide after said step of separating the oxygen gas from the organic intermediate.

Disclosed are nucleic acid sequences comprising a first E. coli homology region, wherein the first E. coli homology region comprises a protospacer adjacent motif (PAM) mutation; a constitutive promoter; a mevalonate-3-kinase (M3K) gene; a mevalonate diphosphate decarboxylase (MVD) gene; and a second E. coli homology region. Disclosed are vectors comprising one or more of the disclosed nucleic acid sequences. Disclosed are recombinant cells comprising a nucleic acid sequence, wherein the nucleic acid sequence comprises a first E. coli homology region, wherein the first E. coli homology region comprises a PAM mutation; a constitutive promoter; a M3K gene; a MVD gene; and a second E. coli homology region.

The invention provides a non-naturally occurring bacterium having decreased or eliminated activity of an enzyme that catalyzes the reaction defined by EC 1.2.7.5, such as aldehyde:ferredoxin oxidoreductase (AOR). Optionally, the bacterium also has decreased or eliminated activity of an enzyme that catalyzes the reaction defined by EC 1.2.1.10 and/or EC 1.1.1.1, such as aldehyde dehydrogenase, alcohol dehydrogenase, or bifunctional aldehyde/alcohol dehydrogenase. The invention further provides methods of producing products by culturing the bacterium in the presence of a gaseous substrate containing one or more of CO, CO.sub.2, and H.sub.2.

The invention provides a genetically modified micro-organism for intracellular biosynthesis of a cellular metabolite, comprising a synthetic error correction system having a penalty gene, whose expression leads to arrested growth or cell death (e.g. a toxin gene) in combination with a survival gene, whose expression provides an antidote that restores cell viability and normal growth (e.g. a cognate antitoxin gene). Alternatively, the system has a survival gene, alone, whose expression is essential for growth (i.e. essential gene). The synthetic error correction system further comprises a biosensor, whose function is to induce expression of the survival gene which leads to cell growth, only, when the cell produces a pre-defined level of a given metabolite. The invention further encompasses: a method for producing the genetically modified micro-organism; a method for producing a cellular metabolite with the genetically modified micro-organism; and use of the genetically modified micro-organism for producing a cellular metabolite.

The invention provides non-naturally occurring microbial organisms having a toluene, benzene, p-toluate, terephthalate, (2-hydroxy-3-methyl-4-oxobutoxy)phosphonate, (2-hydroxy-4-oxobutoxy)phosphonate, benzoate, styrene, 2,4-pentadienoate, 3-butene-1ol or 1,3-butadiene pathway. The invention additionally provides methods of using such organisms to produce toluene, benzene, p-toluate, terephthalate, (2-hydroxy-3-methyl-4-oxobutoxy)phosphonate, (2-hydroxy-4-oxobutoxy)phosphonate, benzoate, styrene, 2,4-pentadienoate, 3-butene-1ol or 1,3-butadiene.

The application describes a method for producing alkenes (for example propylene, ethylene, 1-butylene, isobutylene, isoamylene, butadiene or isoprene) from 3-hydroxy-1-carboxylic acids via 3-sulfonyloxy-1-carboxylic acids.

The present disclosure relates to biosynthetic methods for producing propylene from C.sub.1 substrates (e.g., methane, methanol, carbon monoxide, syngas) and to genetically engineered organisms having propylene biosynthesis capability, as well as engineered organisms having a butyrate/butanol-producing pathway.

In alternative embodiments, provided are genetically or recombinantly engineered nitrogen-fixing, nitrogenase expressing bacteria capable of enzymatically synthesizing hydrocarbons, and methods for making and using them. In alternative embodiments, provided are genetically or recombinantly engineered nitrogen-fixing, nitrogenase expressing bacteria including nitrogen-fixing diazotrophs such as nitrogen-fixing bacteria of the family Pseudomonadaceae, or the genus Azotobacter, for the whole cell synthesis of hydrocarbons and carbon-carbon bonds. In alternative embodiments, nitrogen-fixing, nitrogenase-expressing bacteria used to practice the invention are genetically or recombinantly engineered to express an exogenous nitrogenase express more endogenous nitrogenase or have increased nitrogenase, activity. In alternative embodiments, nitrogen-fixing, nitrogenase-expressing bacteria used to practice the invention are genetically or recombinantly engineered to lack or have decreased molybdenum transporter activity. In alternative embodiments, provided are culture systems, fermenters and bioreactors using nitrogen-fixing, nitrogenase-expressing bacteria for enzymatically synthesizing hydrocarbons.

The invention provides non-natural microbial organisms containing enzymatic pathways and/or metabolic modifications for enhancing carbon flux through acetyl-CoA, or oxaloacetate and acetyl-CoA. Embodiments of the invention include microbial organisms having a pathway to acetyl-CoA and oxaloacetate that includes phosphoketolase (a PK pathway). The organisms also have either (i) a genetic modification that enhances the activity of the non-phosphotransferase system (non-PTS) for sugar uptake, and/or (ii) a genetic modification(s) to the organism's electron transport chain (ETC) that enhances efficiency of ATP production, that enhances availability of reducing equivalents or both. The microbial organisms can optionally include (iii) a genetic modification that maintains, attenuates, or eliminates the activity of a phosphotransferase system (PTS) for sugar uptake. The enhanced carbon flux through acetyl-CoA and oxaloacetate can be used for production of a bioderived compound, and the microbial organisms can further include a pathway capable of producing the bioderived compound.